• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Machine Learning Model Identifies Key Biomarkers Predicting Zoster Nerve Pain Relief

by
November 20, 2026
in Health
Reading Time: 6 mins read
0
Machine Learning Model Identifies Key Biomarkers Predicting Zoster Nerve Pain Relief

Machine Learning Model Identifies Key Biomarkers Predicting Zoster Nerve Pain Relief

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A newly published retrospective investigation in the medical journal Pain and Therapy demonstrates that machine learning algorithms can accurately forecast whether patients suffering from zoster-associated pain will achieve clinical relief following pulsed radiofrequency treatment. Analyzing a substantial observational cohort of 1,773 individuals treated across a seven-year window, researchers established that integrating routine clinical indicators with specific blood markers of lipid metabolism and systemic inflammation yielded superior prognostic precision. Zoster-associated pain is a debilitating neuropathic syndrome that stems from the reactivation of the varicella-zoster virus, affecting approximately sixty-five percent of individuals diagnosed with herpes zoster. When conservative therapies fail, pulsed radiofrequency serves as a key neuromodulatory intervention designed to alleviate neural suffering and halt the progression toward persistent postherpetic neuralgia. Nevertheless, clinical efficacy remains highly heterogeneous across patient populations, creating an urgent clinical imperative to identify reliable physiological indicators capable of separating potential treatment responders from nonresponders prior to undertaking invasive interventional procedures.

To address this prognostic challenge, the research team designed a single-center retrospective study conducted at the First Affiliated Hospital of Wenzhou Medical University following ethical review and the international reporting recommendations of the TRIPOD guidelines. The initial clinical screening identified 2,187 adult patients treated with pulsed radiofrequency between January 2018 and June 2025 who presented with documented zoster rash histories and had demonstrated inadequate therapeutic relief after undergoing at least two weeks of standard pharmacological management. Following the systematic exclusion of 414 individuals due to confounding chronic pain disorders, severe systemic comorbidities such as active malignancies, concurrent psychiatric illnesses, or incomplete electronic medical records, the final analytical cohort comprised 1,773 patients. In total, 1,206 individuals, representing 68.0 percent of the cohort, achieved successful pain relief, whereas 567 patients, or 32.0 percent, experienced treatment failure. Stratified random sampling allocated seventy percent of the cohort, consisting of 1,241 patients, into a training dataset, reserving the remaining thirty percent, or 532 patients, as an independent internal testing set.

Patient outcomes at the primary three-month post-procedure follow-up were classified using explicit criteria guided by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations. Clinical failure, designating nonresponder status, was defined by the occurrence of any one of four standardized adverse markers: residual moderate to severe pain documented as a Numerical Rating Scale score of four or greater, pain-induced sleep disturbances, pain-related emotional disorders, or the clinical necessity for supplementary interventional pain procedures. Baseline data extraction captured forty-seven multidimensional variables encompassing patient demographics, lifestyle factors, chronic comorbid conditions, pharmacological histories, and extensive preoperative laboratory parameters. To eliminate dietary confounding that could alter circulating lipid concentrations, all fasting venous blood draws were drawn in the early morning within seventy-two hours prior to the interventional procedure under standardized conditions of at least eight hours of overnight fasting. Documented opioid administration occurring within one week preceding pulsed radiofrequency was specifically indexed as preoperative opioid use.

Because clinical datasets frequently exhibit high dimensionality and collinearity among physiological measures, the investigators executed a tripartite feature selection workflow to isolate the most robust predictors. This computational framework sequentially coupled the least absolute shrinkage and selection operator regression for L1-regularized dimensional reduction, the random forest-based Boruta algorithm to screen genuine predictive features against randomized shadow attributes, and multivariable logistic regression to ensure independent statistical significance. From the initial pool of forty-seven candidate variables, this rigorous triple-filtering process narrowed the field to a parsimonious signature composed of five core parameters: chronological age, baseline Numerical Rating Scale pain intensity, preoperative opioid analgesic use, circulating apolipoprotein B concentrations, and the peripheral neutrophil-to-monocyte ratio. Highly skewed laboratory counts, including absolute neutrophil and monocyte counts, were normalized using logarithmic transformations, imputed using chained equations, and standardized before being deployed across downstream predictive modeling architectures.

The researchers trained, tuned, and evaluated eight distinct machine learning classifiers: categorical boosting, light gradient boosting, extreme gradient boosting, random forest, k-nearest neighbors, multivariable logistic regression, linear discriminant analysis, and quadratic discriminant analysis. Hyperparameter tuning was conducted across tenfold cross-validation on the training set, optimizing for receiver operating characteristic area under the curve metrics. When evaluated on the unseen internal testing set of 532 patients, the categorical boosting architecture, known as CatBoost, was selected as the optimal predictive engine. CatBoost produced an area under the receiver operating characteristic curve of 0.834, supported by a 95 percent confidence interval spanning 0.792 to 0.871, and an area under the precision-recall curve of 0.898. Although conventional logistic regression produced a marginally higher receiver operating characteristic area of 0.842, CatBoost was chosen because it achieved superior holistic clinimetric balance, securing the highest overall accuracy of 0.793, a sensitivity of 0.884, a specificity of 0.600, a Kappa statistic of 0.504, a Youden index of 0.484, and an overall F1 score of 0.853.

Evaluation of model calibration and real-world clinical utility further substantiated the algorithmic selection of the CatBoost classifier over traditional linear and alternative machine learning alternatives. A calibration curve comparing predicted failure probabilities against observed outcomes demonstrated tight alignment across risk strata, quantified by a favorable Brier goodness-of-fit score of 0.148. Furthermore, standardized decision curve analysis revealed that applying the CatBoost model provided superior net clinical benefit across an extensive span of decision threshold probabilities when directly compared against default assumptions of intervening on all patients or intervening on none. To overcome the traditional black-box limitations of advanced ensemble models, the authors employed Shapley additive explanations to quantify the precise directional impact and clinical weight of each component feature. Global importance rankings demonstrated that documented preoperative opioid use exerted the single largest magnitude of predictive influence shifting outcomes toward treatment failure, followed in order of impact by advanced chronological age, elevated baseline Numerical Rating Scale pain scores, circulating apolipoprotein B concentrations, and the neutrophil-to-monocyte ratio.

The biological rationale underlying the negative predictive impact of preoperative opioid consumption centers on neuroplastic changes associated with opioid-induced hyperalgesia and established central sensitization. Prolonged opioid exposure can paradoxically aggravate pain sensitivity by activating N-methyl-D-aspartate receptors and upregulating spinal dynorphin expression, driving a sensitized neural state that may overwhelm the membrane-stabilizing and microglial-suppressive actions of pulsed radiofrequency neuromodulation. Similarly, advanced chronological age reflects progressive immunosenescence and a compromised endogenous regenerative capacity within peripheral nervous tissues. Elevated baseline pain scores denote extensive initial neural injury that accelerates the transition toward recalcitrant central pain states. Considered together, these findings provide quantitative empirical support for a narrow therapeutic window: once persistent neuropathic pain escalates to levels requiring systemic opioid prescription or high pain ratings, the responsiveness of the peripheral and central nervous systems to pulsed radiofrequency appears substantially diminished.

Conversely, circulating apolipoprotein B emerged as a novel metabolic indicator associated with favorable treatment responses following pulsed radiofrequency. Because apolipoprotein B serves as the primary structural transporter for low-density lipoproteins, its systemic presence provides essential lipid substrates, including cholesterol delivered to Schwann cells, necessary for remyelinating damaged peripheral nerve fibers following acute viral insult. Recent molecular investigations indicate that thermal and mechanical nociceptive transducers, such as TRPV1 and TRPA1 ion channels, are functionally embedded within cholesterol-rich lipid raft domains on neuronal membranes. While localized lipid depletion can temporarily diminish channel activity, enduring recovery from severe varicella-zoster neuropathy requires substantive structural reconstruction. Consequently, adequate baseline lipid availability, indicated by elevated apolipoprotein B concentrations, appears to reflect the physiological metabolic reserve required for effective myelin sheath repair and axonal membrane stabilization during the post-procedural healing phase.

The peripheral neutrophil-to-monocyte ratio demonstrated an inverse association with treatment success, highlighting the deleterious influence of systemic immune-inflammatory dysregulation. A high neutrophil-to-monocyte ratio reflects an elevated circulating neutrophil burden relative to circulating monocytes. In neuropathic disease states, activated neutrophils infiltrate injured sensory pathways and dorsal root ganglia, releasing reactive oxygen species and inflammatory mediators such as tumor necrosis factor-alpha and interleukin-1 beta that sensitize nociceptors and amplify central sensitization. In contrast, monocytes serve as circulating precursors for anti-inflammatory macrophage populations that clear degenerated myelin fragments and release trophic factors necessary for nerve regeneration. When systemic neuroinflammation remains elevated, indicated by a high neutrophil-to-monocyte ratio, the persistent inflammatory environment appears capable of overriding the localized anti-inflammatory and electrical neuromodulatory benefits achieved by pulsed radiofrequency application at the dorsal root ganglion level.

To translate these computational findings into bedside practice, the investigators engineered a freely accessible interactive web-based risk calculator utilizing the Streamlit platform, accompanied by open-access source code. Clinicians can enter a patient’s age, baseline pain score, opioid history, apolipoprotein B level, and neutrophil-to-monocyte ratio to instantly calculate personalized failure probabilities, using a fifty percent probability threshold to identify individuals who may require immediate escalation to advanced therapies such as spinal cord stimulation. Despite these strengths, the authors identified several study limitations, including its retrospective, single-center design, the absence of stage-specific subgroups distinguishing acute herpes zoster from long-standing postherpetic neuralgia, and a lack of granular procedural metrics such as radiofrequency voltage, duration, and temperature. Furthermore, retrospective records precluded exact quantification of cumulative morphine milligram equivalents or antiviral therapy regimens, underscoring the necessity for prospective multicenter trials to validate the model before widespread implementation.

Subject of Research: Machine learning prediction of pulsed radiofrequency efficacy for zoster-associated pain using clinical, lipid, and inflammatory biomarkers

Article Title: A Novel Machine Learning Signature Incorporating Lipid and Inflammatory Biomarkers to Predict Pulsed Radiofrequency Efficacy in Zoster-Associated Pain

Article References: Zhang, L., Chen, H., Chen, H., Hu, W., Zhang, J., Pi, Z., Jin, Y., Peng, Y., Li, L., Lin, H., & Geng, W. (2026). A Novel Machine Learning Signature Incorporating Lipid and Inflammatory Biomarkers to Predict Pulsed Radiofrequency Efficacy in Zoster-Associated Pain. Pain and Therapy, 15(4), 1147-1165. https://doi.org/10.1007/s40122-026-00854-7

Image Credits: AI Generated

DOI: 10.1007/s40122-026-00854-7

Keywords: zoster-associated pain, pulsed radiofrequency, machine learning, CatBoost, apolipoprotein B, neutrophil-to-monocyte ratio, postherpetic neuralgia, neuromodulation, preoperative opioid use, Shapley additive explanations, biomarkers, pain management, retrospective cohort, decision curve analysis, clinical decision support, nerve injury

News Source: Teresa Odom. (November 20, 2026). Machine Learning Model Identifies Key Biomarkers Predicting Zoster Nerve Pain Relief. Scienmag.

Tags: apolipoprotein BbiomarkersCatBoostClinical decision supportdecision curve analysisMachine Learningnerve injuryNeuromodulationneutrophil-to-monocyte ratioPain Managementpostherpetic neuralgiapreoperative opioid usepulsed radiofrequencyRetrospective CohortShapley additive explanationszoster-associated pain
Share12Tweet7Share2ShareShareShare1

Related Posts

Meta-Analysis Finds Half of Surveyed Pakistani Populations Report Insomnia Symptoms

Meta-Analysis Finds Half of Surveyed Pakistani Populations Report Insomnia Symptoms

November 20, 2026
Routine PSA Machine Learning Model Improves Prostate Cancer Triage in Multicenter Study

Routine PSA Machine Learning Model Improves Prostate Cancer Triage in Multicenter Study

November 20, 2026

Standardized Postoperative Ileus Pathway Shows High Adherence in Single-Center Study

November 20, 2026

Parents More Frequently Treat Childhood Fever Than Pain and Prefer Ibuprofen

November 20, 2026

POPULAR NEWS

  • Ethiopian Study Documents 70 Wild Edible Plant Species Across Aseko District

    Ethiopian Study Documents 70 Wild Edible Plant Species Across Aseko District

    29 shares
    Share 12 Tweet 7
  • Meta-Analysis Finds Half of Surveyed Pakistani Populations Report Insomnia Symptoms

    29 shares
    Share 12 Tweet 7
  • Genotype D1 Hepatitis B Virus Protein Mutations Follow Phase-Dependent Structural Shifts

    29 shares
    Share 12 Tweet 7
  • Frequency Ratio Model Outperforms Competing Methods for Himalayan Landslide Susceptibility Mapping

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Ethiopian Study Documents 70 Wild Edible Plant Species Across Aseko District

Meta-Analysis Finds Half of Surveyed Pakistani Populations Report Insomnia Symptoms

Genotype D1 Hepatitis B Virus Protein Mutations Follow Phase-Dependent Structural Shifts

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.